Precision BioLogic's Collaborative Innovation Leading the Way in Hemostasis Diagnosis and Research
Precision BioLogic: A Leader in Hemostasis Diagnostics
Precision BioLogic Inc., renowned for its expertise in developing diagnostic products for hemostasis, is making waves in the medical community. With its subsidiaries, Affinity Biologicals and George King Bio-Medical, the company is capturing the attention of hematologists and researchers focused on blood coagulation worldwide.
Since last autumn, when Precision BioLogic introduced enhanced utility for its CRYOcheck™ Chromogenic Factor VIII assay, interest in its offerings increased significantly. This boost is timely, especially with emerging treatments for hemophilia such as Mim8, a cutting-edge bispecific antibody recently submitted for FDA approval by Nova Nordisk. Precision BioLogic aims to equip laboratories to gain accurate measurements for Factor VIII, including in the presence of long-acting FVIII replacement products and new bispecific antibodies.
Paul Empey, President and CEO of Precision BioLogic, shared insights from their recent participation at ISTH 2026 in Paris. He noted, "Our bovine chromogenic factor VIII assay is designed to accurately measure levels even amidst the evolving treatment landscape of hemophilia A. We are committed to ensuring that coagulation labs have the necessary tools to deliver precise outcomes."
The company's contributions to scientific understanding were further highlighted with the presentation of two impactful posters at ISTH:
1. An Automated Lupus Anticoagulant Assay Resistant to Anticoagulant Drugs Including DOACs and Oral FXI Inhibitors.
2. Impact of Heat-Stable Factor VIII Mimetics and Replacement Therapies on Inhibitor Titer Using a Modified Nijmegen-Bethesda Test Across Bovine Chromogenic FVIII Assays.
Following ISTH, the team showcased their manufacturing capabilities and customized solutions at ADLM 2026 in Anaheim, California. This exposure continues to position Precision BioLogic as a vital player in the hemostasis diagnostics field. Their collaborative efforts also shone through at the NBDF conference in Orlando, Florida, where George King Bio-Medical engaged with families and healthcare professionals to discuss the critical role of plasma donation in advancing research and treatments for bleeding disorders.
As the summer activities conclude, Precision BioLogic, Affinity Biologicals, and George King Bio-Medical reaffirm their commitment to providing reliable products, efficient service, and significant innovations. The synergy among these organizations is directing efforts towards addressing the urgent needs of the hemostasis community worldwide.
About Precision BioLogic
Founded to enhance diagnostic accuracy in coagulation disorders, Precision BioLogic Inc. develops, manufactures, and markets a comprehensive line of frozen CRYOcheck™ products. These diagnostics serve healthcare professionals globally in their quest to tackle bleeding and thrombotic conditions. In November 2018, Precision BioLogic expanded its impact by acquiring Affinity Biologicals, a key player in thrombosis and hemostasis research. Furthermore, in October 2025, the acquisition of George King Bio-Medical further solidified Precision BioLogic’s role in providing advanced diagnostics tailored to the bleeding disorders community. For more information, visit www.precisionbiologic.com.
For press inquiries, please contact Elaine Benoit, Marketing and Communications Manager at Precision BioLogic: [email protected], 902.430.7795.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.